Promising Psoriasis Pipeline Therapies such as Hypericin, EDP1815, Cetaphil, AX-158, HAT1 topical solution, Calcipotriol, ARQ ...

This segment is sponsored by Arcutis Biotherapeutics.Nearly 9 million people in the U.S. have an inflammatory skin condition ...

I use roflumilast for inverse psoriasis and tapinarof for thicker plaque psoriasis." Cheng said insurance considerations often come into play when deciding how to start psoriasis treatment.

Top-line results for the last cohort of patients in the Phase 2a clinical trial in mild-to-moderate psoriasis with SGX302 (synthetic hypericin) in 4Q 2025, where we have already demonstrated the ...

The researchers note that roflumilast is a phosphodiesterase-4 (PDE-4) inhibitor, which targets inflammatory pathways central ...

Psoriasis is a chronic autoimmune condition that mainly affects the skin. When you have psoriasis, your immune system sends ...

Normally, skin cells take about a month to form and rise to the surface. In people with psoriasis, this process happens in ...

Discover a study that demonstrates the effectiveness of guselkumab in treating scalp psoriasis, offering significant symptom ...

References 1. Armstrong AW, Gondo GC, Merola JF, et al. Defining on-treatment remission in plaque psoriasis: A consensus statement from the National Psoriasis Foundation. JAMA Dermatol.

ALEXANDRIA, VA, UNITED STATES, June 2, 2025 /EINPresswire.com/ -- ● The NPF Seal of Recognition highlights products that prove a commitment to being safe and non-irritating for people with psoriasis ...

The U.S. Food and Drug Administration has approved Arcutis Biotherapeutics' Zoryve (roflumilast) topical foam 0.3% for the treatment of plaque psoriasis of the scalp and body in adult and ...

TUESDAY, May 27, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Zoryve (roflumilast) topical foam 0.3 percent for the treatment of plaque psoriasis of the scalp and ...